A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe
Tekijät: Wildenbeest J.G., Zuurbier R.P., Korsten K., van Houten M.A., Billard M.N., Derksen-Lazet N., Snape M.D., Drysdale S.B., Robinson H., Pollard A.J., Heikkinen T., Cunningham S., Leach A., Martinón-Torres F., Rodríguez-Tenreiro Sánchez C., Gómez-Carballa A., Bont L.J.; RESCEU Investigators
Kustantaja: Oxford University Press
Julkaisuvuosi: 2020
Journal: Journal of Infectious Diseases
Tietokannassa oleva lehden nimi: The Journal of infectious diseases
Vuosikerta: 222
Numero: supplement 7
Aloitussivu: S606
Lopetussivu: S612
eISSN: 1537-6613
DOI: https://doi.org/10.1093/infdis/jiaa310
Verkko-osoite: https://doi.org/10.1093/infdis/jiaa310
Background
Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Although prematurity and cardiopulmonary disease are risk factors for severe disease, the majority of infants hospitalized with RSV are previously healthy. Various vaccines and therapeutics are under development and expected to be available in the near future. To inform the use of these new vaccines and therapeutics, it is necessary to determine the burden of RSV disease in Europe. We will prospectively follow-up a birth cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).
Methods
Multicenter prospective study of a birth cohort consisting of 10 000 healthy infants, recruited during 3 consecutive years. RSV associated hospitalization in the first year of life will be determined by questionnaires and hospital chart reviews. A nested cohort of 1000 infants will be actively followed. In case of ARTI, a respiratory sample will be collected for RSV molecular diagnosis.
Results
The primary outcome is the incidence rate of RSV-associated hospitalization in the first year of life. In the active cohort the primary outcome is RSV associated ARTI and MA-ARTI.
Conclusions
We will provide key information to fill the gaps in knowledge about the burden of RSV disease in healthy infants.
Clinical Trials Registration
NCT03627572.
